
CLAIMS

1. Use of a compound of following general formula (I):



(I)

or a pharmaceutically acceptable salt and/or solvate thereof, wherein:


- Het is a nitrogen-containing heterocycloalkyl;
- X is a single bond, a (C_1-C_6)alkyl group or a (C_1-C_6)alkoxy group, in particular a single bond, a (C_1-C_3)alkyl group or a (C_1-C_3)alkoxy group;
- Y is a group selected from $–R_{10}C(O)NHR_{11}$; $–R_{10}C(O)NR_{11}$; (C_1-C_6)alkyl; or (C_1-C_6)alkyl-aryl with (C_1-C_6)alkyl optionally substituted with =O, =S or a phenyl and with aryl optionally substituted with one or several substituents selected from hydrogen atom, halo,-CN, $-NO_2$, $-OR_{12}$, $-NR_{13}R_{14}$, $-C(O)OR_{15}$, $-C(O)NR_{16}R_{17}$, $-S(O)_2NR_{18}R_{19}$, $-S(O)_2R_{20}$, $-NHS(O)_2R_{21}$, $-NHC(O)R_{22}$, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle, (C_1-C_6)alkyl-heterocycle, said group being optionally substituted with one or several groups selected from halo, (C_1-C_6)alkyl, $-OR_{23}$ or $-OC(O)R_{24}$, or with two adjacent substituents which form together with the carbon atoms to which they are chemically linked an heterocycle;
- R_1 to R_4 are, independently of one another, hydrogen atom or a group selected from halo, $-NO_2$, –CN, $-OR_{25}$, $-NR_{26}R_{27}$, $-C(O)OR_{28}$, $-S(O)_2R_{29}$, or a (C_1-C_6)alkyl group optionally substituted with one or several groups selected from halo or $–OR_{30}$;
- R_{10} to R_{30} are, independently of one another, hydrogen atom, halo, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle, (C_1-C_6)alkyl-heterocycle, said group being optionally substituted with one or several groups selected from halo, (C_1-C_6)alkyl, CF_3 or $–OR_{31}$;

- R_{31} is hydrogen atom, halo or a (C_1-C_6)alkyl group;

in the manufacture of a medicament for the prevention and/or the treatment of disorders associated to the inflammation induced by *P. acnes*, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

2. The use according to claim 1, wherein Y is (C_1-C_6)alkyl-phenyl optionally substituted with one or several substituents, preferably one to four substituents, notably one or two substituents, selected from hydrogen atom, halo,-CN, -NO_2, -OR_{12}, -$NR_{13}R_{14}$, -$C(O)NR_{16}R_{17}$, -$S(O)_2NR_{18}R_{19}$, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle or (C_1-C_6)alkyl-heterocycle.

3. The use according to claim 1 or 2, wherein said compound is of the following general formula (Ia):




(Ia)

or a pharmaceutically acceptable salt and/or solvate thereof, wherein:

- Het is a nitrogen-containing heterocycloalkyl; and
- R_1 to R_9 are as defined in claim 1.

4. The use according to any one of claims 1 to 3, wherein Het is a piperazinyl or a piperidinyl.

5. The use according to any one of claims 1 to 4, wherein said compound is of the following general formula (Ib):



(Ib),


or a pharmaceutically acceptable salt and/or solvate thereof, R_1 to R_9 being as defined in claim 1.

6. The use according to any one of claims 1 to 5, wherein R_1 to R_4 are, independently of one another, hydrogen atom or a group selected from halo, $-NO_2$, –CN, $-OR_{25}$, $-NR_{26}R_{27}$ or a (C_1-C_6)alkyl group, in particular R_1 to R_4 are, independently of one another, hydrogen atom or a group selected from halo, $-OR_{25}$, $-NR_{26}R_{27}$ or a (C_1-C_6)alkyl group, more particularly R_1 to R_4 are, independently of one another, hydrogen atom or halo; R_{25} to R_{27} being as defined in claim 1.

7. The use according to any one of claims 3 to 6, wherein R_5 to R_9 are, independently of one another, hydrogen atom, halo, -CN, $-NO_2$, $-OR_{12}$, $-NR_{13}R_{14}$, $-C(O)NR_{16}R_{17}$, $-S(O)_2NR_{18}R_{19}$, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle or (C_1-C_6)alkyl-heterocycle; preferably R_5 to R_9 are, independently of one another, hydrogen atom, halo,-CN, $-NO_2$, $-OR_{12}$, $-NR_{13}R_{14}$, $-C(O)NR_{16}R_{17}$, $-S(O)_2NR_{18}R_{19}$, or a group selected from (C_1-C_6)alkyl, heterocycle or (C_1-C_6)alkyl-heterocycle; more particularly R_5 to R_9 are, independently of one another, hydrogen atom, halo, $-OR_{12}$, $-NR_{13}R_{14}$ or a (C_1-C_6)alkyl group; R_{13} to R_{19} being as defined in claim 1.

8. The use according to any one of claims 1 to 7, wherein R_{10} to R_{30} are, independently of one another, hydrogen atom, halo, or a group selected from (C_1-C_6)alkyl.


9. The use according to any one of claims 1 to 8, wherein said compound is of the following formula (Ic):



(Ic),

or a pharmaceutically acceptable salt and/or solvate thereof, preferably it is the dihydrochloride salt of compound (Ic).

10. Use of a compound of following general formula (II):



(II)


or a pharmaceutically acceptable salt and/or solvate thereof, wherein:

- X', Y' and Z' are, independently of one another, CH, CH_2, NH or N;
- W' is CH or SH;
- R'$_1$ and R'$_2$ are, independently of one another, hydrogen atom, halo,-CN, -NO_2, -CF_3, -OR'$_7$, -NR'$_8$R'$_9$, or a (C_1-C_6)alkyl group;
- R'$_3$ is H, -CN, =O, OR'$_{10}$, or a (C_1-C_6)alkyl group;
- R'$_4$ and R'$_5$, are, independently of one another, hydrogen atom or a group selected from halo, -NO_2, –CN, -OR'$_{11}$, -NR'$_{12}$R'$_{13}$, -C(O)OR'$_{14}$, -$S(O)_2$R'$_{15}$, or a (C_1-C_6)alkyl group optionally substituted with one or several groups selected from halo or –OR'$_{16}$;

- R'$_7$ to R'$_{16}$ are, independently of one another, hydrogen atom or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle, (C_1-C_6)alkyl-heterocycle, said group being optionally substituted with one or several groups selected from halo, (C_1-C_6)alkyl, CF_3 or –OR'$_{17}$;
- R'$_{17}$ is hydrogen atom, halo or a (C_1-C_6)alkyl group;

in the manufacture of a medicament for the prevention and/or the treatment of disorders associated to the inflammation induced by *P. acnes*, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

11. The use according to claim 10, wherein said compound is of the following general formula (IIa):



(IIa)

or a pharmaceutically acceptable salt and/or solvate thereof, wherein:

- X', Y' and Z' are, independently of one another, CH, CH_2, NH, or N;
- R'$_1$ and R'$_2$ are, independently of one another, hydrogen atom, halo,-CN, -NO_2, -CF_3, -OR'$_7$, -NR'$_8$R'$_9$, or a (C_1-C_6)alkyl group;
- R'$_3$ is H, -CN, =O, OR'$_{10}$, or a (C_1-C_6)alkyl group;
- R'$_4$ and R'$_5$, are, independently of one another, hydrogen atom or a group selected from halo, -NO_2, –CN, -OR'$_{11}$, -NR'$_{12}$R'$_{13}$, -C(O)OR'$_{14}$, -S(O)$_2$R'$_{15}$, or a (C_1-C_6)alkyl group optionally substituted with one or several groups selected from halo or –OR'$_{16}$;
- R'$_7$ to R'$_{16}$ are, independently of one another, hydrogen atom, or a group selected from (C_1-C_6)alkyl, aryl, (C_1-C_6)alkyl-aryl, heterocycle, (C_1-C_6)alkyl-heterocycle, said group being optionally substituted with one or several groups selected from halo, (C_1-C_6)alkyl, CF_3 or –OR'$_{17}$;

- R'_{17} is hydrogen atom, halo or a (C_1-C_6)alkyl group.


12. The use according to claim 10 or 11, wherein X', Y' and Z' are a nitrogen atom.

13. The use according to any one of claims 10 to 12, wherein R'_3 is –CN, =O, or OH, preferably R'_3 is -CN.


14. The use according to any one of claims 10 to 13, wherein R'_1 and R'_2 are, independently of one another, hydrogen atom, halo,-CF_3, -OH, or a (C_1-C_6)alkyl group; preferably R'_1 and R'_2 are, independently of one another, hydrogen atom or halo; more preferably R'_1 and R'_2 are, independently of one another, hydrogen atom or Cl.

15. The use according to any one of claims 10 to 14, wherein R'_5 is an hydrogen atom and R'_4 is selected from the group consisting of hydrogen atom, halo,-CF_3, -OH, and a (C_1-C_6)alkyl group; preferably R'_5 is an hydrogen atom and R'_4 is an hydrogen atom or halo; more preferably R'_5 is an hydrogen atom and R'_4 is an hydrogen atom or Cl.

16. The use according to any one of claims 10 to 15, wherein said compound is of the following general formula (IIb) or (IIc):




(IIb),



(IIc),

or a pharmaceutically acceptable salt and/or solvate thereof.

17. The use according to any one of claims 10 to 16, wherein said compound is of the following formula (IId):



(IId),

or a pharmaceutically acceptable salt and/or solvate thereof.

18. A pharmaceutical composition comprising at least one compound according to any one of claims 1 to 9 and/or one compound according to any one of claims 10 to 17 and at least one pharmaceutically acceptable excipient, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by *P. acnes*, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.

19. The pharmaceutical composition for use according to claim 18, wherein it further comprises another active principle, such as topical antibiotic (erythromycine, dalacine), topical anti-inflammatory (benzoyl peroxydes derivatives), topical anti-seborrheic (isotretinoin, tretinoin, adapalene), zinc derivatives (zinc gluconate), cyclins, or isotretinoin.